{"id":353171,"date":"2010-02-23T09:48:45","date_gmt":"2010-02-23T14:48:45","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=64645"},"modified":"2010-02-23T09:48:45","modified_gmt":"2010-02-23T14:48:45","slug":"aveo-sets-ipo-price-range-at-13-15-a-share","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/353171","title":{"rendered":"Aveo Sets IPO Price Range at $13-$15 a Share"},"content":{"rendered":"\n
Life Sciences<\/a>, IPO<\/a>, cancer<\/a><\/div>\n

\t\tRyan McBride wrote:<\/strong><\/p>\n

Aveo Pharmaceuticals, a Cambridge, MA-based developer of cancer drugs, has set a price range of $13 to $15 per share for its proposed initial public offering, according to an SEC filing<\/a>. The firm says it expects to offer 7 million shares in the IPO, in addition to up to 1.05 million shares that would be sold to cover over-allotments. At $15 a share, the public debut could bring in a total of $120.75 million, according to the company. The company—which estimated it would raise $86.3 million in the IPO when it first revealed its plans to go public in December 2009<\/a>—plans to list its stock on the NASDAQ stock market under the symbol “AVEO.”<\/p>\n

Comments (1)<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Life Sciences, IPO, cancer Ryan McBride wrote: Aveo Pharmaceuticals, a Cambridge, MA-based developer of cancer drugs, has set a price range of $13 to $15 per share for its proposed initial public offering, according to an SEC filing. The firm says it expects to offer 7 million shares in the IPO, in addition to up […]<\/p>\n","protected":false},"author":2829,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-353171","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/353171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2829"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=353171"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/353171\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=353171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=353171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=353171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}